IBIO INC. DL -,001

Action · US4510337086 · IBIO · A3E2GR (XASE)

Aperçu

Analyse alimentée par l’IA

Analyse fondamentale

Découvrez ce que disent vraiment les chiffres — avant le marché

Analyser maintenant

Sentiment des actualités

Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?

Analyser maintenant

Acheter / Conserver / Vendre

Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.

Analyser maintenant

Évaluation des risques

Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.

Analyser maintenant

Juste valeur

Cette action est-elle bon marché, correctement valorisée ou surévaluée ?

Analyser maintenant

Dernières analyses d’IA sur IBIO INC. DL -,001

Résumé de la Note des Analystes

Achat

Achat fort

Achat

Conserver

Vente

Vente forte

Pas de cours

29.04.2026 16:28

Cours actuels de IBIO INC. DL -,001

Bourse	Ticker	Devise	Dernier échange	Cours	Variation journalière
IEX	IBIO	USD	29.04.2026 16:28	1,62 USD	-0,01 USD -0,92 %
NYSE	IBIO	USD	29.04.2026 16:13	1,61 USD	-0,02 USD -1,53 %
NASDAQ	IBIO	USD	29.04.2026 16:12	1,61 USD	-0,02 USD -1,53 %

Flottant et Liquidité des Actions

Flottant Libre 94,61 %

Actions en Flottant 14,94 M

Actions en Circulation 15,79 M

Profil de l'entreprise pour IBIO INC. DL -,001 Action

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.